High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer
- 15 September 2005
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 57 (5) , 640-646
- https://doi.org/10.1007/s00280-005-0093-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Gemcitabine Plus Cisplatin for the Treatment of Metastatic Breast CancerClinical Breast Cancer, 2002
- Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II TrialOncology, 2002
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerThe Breast, 2000
- Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer PatientsJournal of Clinical Oncology, 2000
- Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell linesBritish Journal of Cancer, 1999
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958